SKINBIOTHERAPEUTICS PLC (SBTX) — Interim Results

Investor webinar replay

Replay transcript excerpt

Good afternoon, and welcome to the SKINBIOTHERAPEUTICS PLC interim results investor presentation. Throughout this recorded presentation, investors will be in listen only mode. Questions are encouraged and can be submitted at any time by the q and a tab situated in the right hand corner of your screen. Just simply type in your questions and press send. The company may not be in a position to answer every question it receives during the meeting itself. However, the company can review all the questions submitted today and publish responses where it's appropriate to do so. Before we begin, I'd like to submit the following poll. I'd now like to hand you over to Stuart Ashman, CEO. Good afternoon to you, sir. Good afternoon. Thank you all for joining us today as we present our interim results. I'd like to give a a short introduction to who we are and what it is that we do for those of you who are new to the company, and then I'll give a general update on where we are following on from this morning's RNS. So my name is Stuart Ashman. I'm the chief executive of the company. I have about twenty seven years experience in in life sciences medical devices, generally speaking, the commercialization of complex science. I'm often the sort of bridge between r and d teams and the commercial and sales team, often the architect of strategies to bring products to the market at the right time, the right place, right price. Often that's supported by strategic mergers and acquisitions. Previously led the innovation teams at and the mergers and acquisition teams at Smith and Nephew and then again at BSN Medical in life sciences and and wound care. And I joined the company a little over four years ago when we were ready to move into the strategic development stage. Prior to joining this comp...